Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.6% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price dropped 3.6% during mid-day trading on Monday . The company traded as low as $6.69 and last traded at $6.69. Approximately 969,449 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 5,749,319 shares. The stock had previously closed at $6.94.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several recent analyst reports. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, July 11th. Finally, Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $9.40.

Recursion Pharmaceuticals Trading Down 2.6 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The business's 50 day simple moving average is $6.73 and its 200 day simple moving average is $7.76. The stock has a market cap of $1.61 billion, a P/E ratio of -4.23 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the previous year, the business earned ($0.38) earnings per share. Recursion Pharmaceuticals's revenue for the quarter was up 30.9% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the sale, the chief executive officer now directly owns 762,656 shares of the company's stock, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Christopher Gibson sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the transaction, the chief financial officer now owns 1,377,756 shares of the company's stock, valued at $8,500,754.52. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 213,129 shares of company stock worth $1,430,004. 15.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in RXRX. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $26,000. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank increased its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $69,000. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.